Evaluation of the clinical therapeutic effect of Vigabatrin (Ocoda) on infantile spasms

Vigabatrin (Vigabatrin) is a γ-aminobutyric acid (GABA) aminotransferase inhibitor. It inhibits GABAdegrades and increases the level of the inhibitory neurotransmitter GABA in the brain, thereby inhibiting abnormal nerve discharges and treating infantile spasms (Infantile Spasms, IS) have significant anticonvulsant effects. As one of the first-choice drugs, Vigabatrin is clinically mainly used in patients with infantile spasms who do not respond well to ACTH or other anti-epileptic drugs, especially those with TSC (tuberous sclerosis complex).

Clinical studies have shown that Vigabatrin can significantly reduce or completely control infantile spasms. In multi-center clinical trials, about half to two-thirds of infant patients can achieve a significant reduction or complete disappearance of spasms after treatment with Vigabatrin. At the same time, electroencephalogram (EEG) examination showed that the spastic wave-like activity of most patients was significantly weakened, and some patients even returned to normal brain electrical background activity, suggesting that drugs have potential benefits in improving neurological abnormalities.

The therapeutic effect of Vigabatrin is closely related to the dosage and timing of treatment. It is generally recommended to initiate treatment as early as possible after a confirmed diagnosis to improve clinical remission rates. Dosage needs to be individually adjusted based on body weight and tolerance, and visual function and blood parameters should be closely monitored during treatment. Long-term follow-up showed that patients who started treatment early were better at controlling spasticity, improving developmental outcomes, and reducing the risk of secondary epilepsy than those who started treatment later.

Despite its remarkable efficacy, vigabatrin needs to be paid attention to potential side effects during use. The main safety concern is retinitis pigmentosa, which can cause permanent vision impairment, so regular eye exams should be performed before and during treatment. Other common side effects include drowsiness, decreased appetite, weight gain, and mild behavioral abnormalities. Taken together, Vigabatrin has a clear effect in the treatment of infantile spasms, but it needs to be combined with strict monitoring and individualized dosage management to maximize the efficacy while ensuring medication safety.

Reference link:https://www.drugs.com